ReviewInternational journal of molecular sciences2015
Mesenchymal stem cells and induced pluripotent stem cells as therapies for multiple sclerosis.
Review in International journal of molecular sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 65 citations in OpenAlex.
- Clinical translational research on stem cell products: prospects and challenges.Signal transduction and targeted therapy · 2026Review
- Cellular Immunotherapies for Multiple Sclerosis: Mechanistic Insights and Clinical Advances.International journal of molecular sciences · 2026Review
- Synergistic myelin regenerative, immunomodulatory and anti-inflammatory effects of vanillin and adipose derived stem cells in cuprizone animal model of multiple sclerosis.Iranian journal of basic medical sciences · 2026Article
- Stem cell-derived extracellular vesicles as immunomodulators: a novel paradigm for post-myocardial infarction repair and regeneration.Frontiers in pharmacology · 2026Review
- Cell Therapy in Multiple Sclerosis: Clinical Advances, Limitations, and Future Perspectives from Clinical Studies-A Systematic Review.Pharmaceutics · 2025Review
- Advancements in Stem Cell Research for Effective Therapies Against Alzheimer's Disease: Current Investigation and Future Insight.Molecular neurobiology · 2025Review
- Primary Progressive Multiple Sclerosis: New Therapeutic Approaches.Neuropsychopharmacology reports · 2025Review
- Recent advances in mesenchymal stem cell therapy for multiple sclerosis: clinical applications and challenges.Frontiers in cell and developmental biology · 2025Review
- Exosomes with Engineered Brain Derived Neurotrophic Factor on Their Surfaces Can Proliferate Menstrual Blood Derived Mesenchymal Stem Cells: Targeted Delivery for a Protein Drug.The protein journal · 2024Article
- Olig2Journal of Zhejiang University. Science. B · 2024Article
- Advances in Genetic Reprogramming: Prospects from Developmental Biology to Regenerative Medicine.Current medicinal chemistry · 2024Review
- Mesenchymal stem cell therapy: A review of clinical trials for multiple sclerosis.Regenerative therapy · 2022Review
- Non-Cytokine Protein Profile of the Mesenchymal Stem Cell Secretome That Regulates the Androgen Production Pathway.International journal of molecular sciences · 2022Article
- Mesenchymal Stromal Cells Combined With Elastin-Like Recombinamers Increase AngiogenesisFrontiers in bioengineering and biotechnology · 2022Article
- Potential of Cellular Therapy for ALS: Current Strategies and Future Prospects.Frontiers in cell and developmental biology · 2022Review
- Mesenchymal stem cell therapy ameliorates metabolic dysfunction and restores fertility in a PCOS mouse model through interleukin-10.Stem cell research & therapy · 2021Article
- The Role of Low-Level Laser Therapy in the Treatment of Multiple Sclerosis: A Review Study.Journal of lasers in medical sciences · 2021Review
- Stem cell therapy for Alzheimer's disease.World journal of stem cells · 2020Review
- Human ES-derived MSCs correct TNF-α-mediated alterations in a blood-brain barrier model.Fluids and barriers of the CNS · 2019Article
- Studying Human Neurological Disorders Using Induced Pluripotent Stem Cells: From 2D Monolayer to 3D Organoid and Blood Brain Barrier Models.Comprehensive physiology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
Multiple sclerosis (MS) is a chronic, autoimmune, inflammatory demyelinating disorder of the central nervous system that leads to permanent neurological deficits. Current MS treatment regimens are insufficient to treat the irreversible neurological disabilities. Tremendous progress in the experimental and clinical applications of cell-based therapies has recognized stem cells as potential candidates for regenerative therapy for many neurodegenerative disorders including MS. Mesenchymal stem cells (MSC) and induced pluripotent stem cell (iPSCs) derived precursor cells can modulate the autoimmune response in the central nervous system (CNS) and promote endogenous remyelination and repair process in animal models. This review highlights studies involving the immunomodulatory and regenerative effects of mesenchymal stem cells and iPSCs derived cells in animal models, and their translation into immunomodulatory and neuroregenerative treatment strategies for MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.